Your browser doesn't support javascript.
loading
A randomized controlled trial of a weight loss maintenance program in adults with obesity: the WLM3P study.
Pereira, Vanessa; Barreiros-Mota, Inês; Cortez, Filipa; Castela, Inês; Teixeira, Diana; Calhau, Conceição; Camila Dias, Cláudia; Moreira-Rosário, André; Silvestre, Marta P.
Afiliación
  • Pereira V; NOVA Medical School, Faculty of Medical Sciences, NMS, FMC, Nova University of Lisbon, Lisbon, Portugal.
  • Barreiros-Mota I; Nutrition Department Farmodiética, Farmodiética, 2785-723, Lisbon, Portugal.
  • Cortez F; NOVA Medical School, Faculty of Medical Sciences, NMS, FMC, Nova University of Lisbon, Lisbon, Portugal.
  • Castela I; CHRC, NOVA Medical School, Faculty of Medical Sciences, NMS, FMC, Nova University of Lisbon, Lisbon, Portugal.
  • Teixeira D; Nutrition Department Farmodiética, Farmodiética, 2785-723, Lisbon, Portugal.
  • Calhau C; Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal.
  • Camila Dias C; NOVA Medical School, Faculty of Medical Sciences, NMS, FMC, Nova University of Lisbon, Lisbon, Portugal.
  • Moreira-Rosário A; CHRC, NOVA Medical School, Faculty of Medical Sciences, NMS, FMC, Nova University of Lisbon, Lisbon, Portugal.
  • Silvestre MP; NOVA Medical School, Faculty of Medical Sciences, NMS, FMC, Nova University of Lisbon, Lisbon, Portugal.
Eur J Clin Nutr ; 78(8): 694-702, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38844671
ABSTRACT
BACKGROUND/

OBJECTIVES:

The escalating obesity epidemic necessitates effective, sustainable weight loss (WL) and maintenance strategies. This study aimed to evaluate the effectiveness of the Weight Loss Maintenance 3 Phases Program (WLM3P) in achieving a clinically significant long-term weight loss (WL) (≥5% initial WL at 18 months) in adults with obesity compared to a standard low-carbohydrate diet (LCD). SUBJECTS/

METHODS:

In this two-phase trial, 112 participants targeting initial WL (0-6 months) and subsequent maintenance (7-18 months) were randomly assigned to either WLM3P or LCD groups. Outcomes assessed included change in body weight (kg, %), improvements in body composition, and metabolic profile.

RESULTS:

Of 112 randomized participants, 69% (n = 77) completed the study. At 18 months, WL in the WLM3P group (n = 40) was 15.5 ± 8.3% compared to 9.6 ± 8.5% in the LCD group (n = 37) (p < 0.001). The odds ratio of achieving WL ≥ 10% and ≥15% were significantly higher in the WLM3P group. Complete-case analysis revealed significantly greater improvements in BMI, body fat mass, visceral fat area, waist circumference, waist-to-hip ratio, HDL, and triglyceride/HDL ratio in WLM3P than in LCD. No serious adverse events were reported.

CONCLUSION:

Both programs effectively promoted clinically relevant WL and its maintenance. However, the WLM3P program was more successful in helping participants achieve greater WL targets of ≥10% and ≥15%, along with other clinical benefits, after an 18-month intervention. TRIAL REGISTRATION NUMBER NCT04192357.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pérdida de Peso / Programas de Reducción de Peso / Obesidad Idioma: En Revista: Eur J Clin Nutr Asunto de la revista: CIENCIAS DA NUTRICAO Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pérdida de Peso / Programas de Reducción de Peso / Obesidad Idioma: En Revista: Eur J Clin Nutr Asunto de la revista: CIENCIAS DA NUTRICAO Año: 2024 Tipo del documento: Article